Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSYCHED-PAL: Psilocybin Microdosing for Psychological Distress in Palliative Care
NCT04754061Phase 2Active, not recruiting
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Jan 2024
- Primary completion
- Oct 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of psilocybin in psychological distress, major depressive disorder (MDD) and anxiety disorder, sponsored by Ottawa Hospital Research Institute. Primary endpoints: Recruitment Rate up to 1 year, Intervention Completion Rate up to 13 months and 10 more. Started Jan 2024; status: active, not recruiting.
02
Drugs
psilocybin
03
Conditions
psychological distressmajor depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on NCT04754061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04754061.